Rifalazil

Summary

Rifalazil (CHEMBL236297) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including intermittent vascular claudication and chlamydia trachomatis infectious disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 3
• Chemistry: 941.1 Da · C51H64N4O13

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL236297
Name	Rifalazil
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	135431094
Molecular formula	C51H64N4O13
Molecular weight	941.1
InChIKey	IXSVOCGZBUJEPI-HTQYORAHSA-N

SMILES: C[C@H]1/C=C/C=C(\C(=O)NC2=C3C(=C4C(=C(C(=C5C4=C([C@](O5)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)C)O)C2=O)N=C6C(=CC(=CC6=O)N7CCN(CC7)CC(C)C)O3)/C

IUPAC name: [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,6,15,17-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-30-[4-(2-methylpropyl)piperazin-1-yl]-23,32,37-trioxo-8,27,38-trioxa-24,34-diazahexacyclo[23.11.1.14,7.05,36.026,35.028,33]octatriaconta-1,3,5,9,19,21,25,28,30,33,35-undecaen-13-yl] acetate

Also known as: KRM-1648, Rifalazil, Rifalazilo, rifalazil, RIFALAZIL, NA

Patent coverage: 414 distinct patent families (1,513 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 1,488 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: DNA-directed RNA polymerase subunit beta.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
intermittent vascular claudication	3	MONDO:0005295	EFO:0003876
chlamydia trachomatis infectious disease	2	MONDO:0005701	EFO:0007205

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE2	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00251849	PHASE3	UNKNOWN	PROVIDENCE-1: Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients
NCT00385385	PHASE2	UNKNOWN	RESTORE-IT-Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients With a History of Atherosclerotic Disease
NCT01631201	PHASE2	COMPLETED	Safety and Efficacy Study of Rifalazil for the Treatment of Chlamydia Trachomatis Infection in Women

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).